Value of N-terminal pro-B-type natriuretic peptide in detecting silent ischemia and its prognostic role in asymptomatic patients with type 2 diabetes mellitus

Acta Endocrinologica

Volumn 7, Issue 2, 2011, Pages 209-218

  Babes, E ^a   Babes, V ^a   Popescu, M ^a   Ardelean, A ^a  

^a UNIVERSITY OF ORADEA   (Romania)

Author keywords

Diabetes; NT proBNP; Prognostic; Silent ischemia

Indexed keywords

EID: 84861090792     PISSN: 18410987     EISSN: None     Source Type: Journal    
DOI: 10.4183/aeb.2011.209     Document Type: Article

References (21)

1. Stamler J, Vaccaro O, Neaton JD, Wentworlh D. Diabetes, other risk factors and 12 yr cardiovascular mortality for men screened in the Multiple Risk factor Intervention Trial. Diabetes Care 1993, 16; 434-444. (Pubitemid 23046633)
2. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999; 111:406-416. (Pubitemid 29446883)
3. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Stramctz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E and Pacher R. Prognostic evaluation of neurohormonal plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436-442. (Pubitemid 32721772)
4. Goctzc J.P, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, and Nielsen LB. Increased cardiac BNP-exprcssion associated with myocardial ischemia. FASEB J 2003, 17(9): 1105-1107.
5. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B and Whooley M. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the heart and soul study. Circulation 2003; 108: 2987-2992. (Pubitemid 37553567)
6. Wcbcr M, Dill T, Arnold R, Rau M, Ekinci O, Mullcr KD, Berkovitsch A, Mitrovic V, Hamm C. N terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004, 148(4): 612-620. (Pubitemid 39349380)
7. Bayes-Genis A, Januzzi J.L, Jr. NT-proBNP as a biomarker in Cardiovascular Diseases. Thomson Reuters, 2008 Prous Science, 101-129.
8. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA,Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663. (Pubitemid 38364624)
9. Tarnow L, Gall M.A, Hansen B.V, Hovind P, Parving H.H. Plasma N terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006, 49: 2256-2262. (Pubitemid 44359085)
10. Kragelund C, Gronning B, Omland T, Kober L, Strande S, Steffensen R, Hildebrandt P. Is N terminal B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary artery disease? Am Heart J 2006, 151 (3): 712 e1-e7.
11. .Wolber T, Maeder M, Rickli H, Riesen W, Binggcli C, Duru F. and Ammann P. N terminal pro-brain natriuretic peptide used for the prediction of coronary artery stenosis. Eur J Clin Invest 2007, 37(1): 18-25. (Pubitemid 44934768)
12. Fcringa H.H, Elhendy A, Bax J.J, Bocrsma E, de Jonge R, Olaf S, Karagiannis SE, Schinkel AFL, Lindemans J, Poldennans D. Baseline plasma N terminal pro-B-type natriuretic peptide is associated with the extent of stress induced myocardial ischemia during dobutamine stress echocardiography. Coron Artery Dis 2006, 17(3): 255-259. (Pubitemid 44324836)
13. Chatka K, Alsoud M, Grifffiths M.J, Elfatih A, Abozguia K, Horton RC, Dunmore SJ, Gama R. B type natriuretic peptide in reversible myocardial ischemia. J Clin Pathol 2006, 59(11): 1216-1217. (Pubitemid 44787149)
14. Sabatine M.S, Morrow D.A, de Lemos J. A, Omland T, Desai MY, Tanasijevic M, Hall C, McCabe CH and Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004,44(10): 1988-1995. (Pubitemid 39473283)
15. Karabinos I, Karvouni E, Chiotinis N, Papadopoulos A, Simeonidis P, Tsolas O and Katritsis D. Acute changes in N terminal pro-brain natriuretic peptide induced by dobutamine stress echocardiography. Eur J Echocardiogr 2007, 8(4): 265-274. (Pubitemid 46969890)
16. Beer S, Golay S, Bardy D, Feihl F, Gaillard RC, Bachmann C, Waeber B, Ruiz J. Increased plasma levels of N-terminal brain natriuretic peptide in type 2 diabetic patients with vascular complications. Diabetes Metab 2005, 31: 567-573. (Pubitemid 43001174)
17. Hamano K., Abe M., Komi R. and Kobayasi S. N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) for predicting silent myocardial ischaemia in type 2 diabetes mellitus independent of microalbuminuria. Diabetes/Metabolism Research and Reviews 2010, 26: 534-539.
18. Cosson E., Nguyen M. T., Pham I, Pontet M., Nitenberg A. and Valensi P. N-tcrminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabetic Medicine 2009, 26: 872-879.
19. Kragelund C, Gustafsson I, Omland T, Gronning B, Kober L, Fabcr J, Strande S, Steffensen R and Hildebrandt P. Prognostic value of N-terminal pro B-type natriuretic peptide in patients with diabetes and stable coronary heart disease. Diabetes Care 2006, 29(6): 1411-1413. (Pubitemid 44125950)
20. Gaede P, Hildebrandt P, Hess G, Parving H-H, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005,48: 156-163. (Pubitemid 40174668)
21. Pfister R, Tan D, Thekkanal J, Hellmich M, Erdmann E, Schneider CA. NT-proBNP measured at discharge predicts outcome in multimorbid diabetic in patients with a broad spectrum of cardiovascular disease. Acta Diabetol 2007; 44:91-97. (Pubitemid 46835451)